News stories about Dicerna Pharmaceuticals (NASDAQ:DRNA) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Dicerna Pharmaceuticals earned a news sentiment score of 0.01 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 46.5841637218156 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Shares of Dicerna Pharmaceuticals (DRNA) traded up 2.40% during mid-day trading on Thursday, hitting $3.42. 93,066 shares of the company’s stock traded hands. Dicerna Pharmaceuticals has a 1-year low of $2.42 and a 1-year high of $6.10. The stock has a 50 day moving average price of $3.44 and a 200-day moving average price of $3.17. The stock’s market cap is $71.29 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last announced its quarterly earnings data on Thursday, August 10th. The biopharmaceutical company reported ($1.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.61) by $0.54. The business had revenue of $0.25 million during the quarter, compared to analyst estimates of $0.08 million. Dicerna Pharmaceuticals had a negative return on equity of 168.65% and a negative net margin of 8,474.12%. The business’s revenue for the quarter was up 2400.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.75) EPS. Equities research analysts anticipate that Dicerna Pharmaceuticals will post ($2.70) EPS for the current fiscal year.

A number of analysts recently commented on the stock. Zacks Investment Research downgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Chardan Capital reissued a “hold” rating on shares of Dicerna Pharmaceuticals in a report on Monday, August 14th. ValuEngine downgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 23rd. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $6.35.

ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Impact Dicerna Pharmaceuticals (DRNA) Share Price” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/07/somewhat-favorable-news-coverage-somewhat-unlikely-to-impact-dicerna-pharmaceuticals-drna-share-price.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Stock Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.